.

Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Cipla
Cantor Fitzgerald
McKesson
Farmers Insurance
Daiichi Sankyo
AstraZeneca
Dow
Cerilliant
Queensland Health

Generated: November 22, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 062298

« Back to Dashboard
NDA 062298 describes ERY-TAB, which is a drug marketed by Arbor Pharms Llc and is included in one NDA. It is available from eight suppliers. Additional details are available on the ERY-TAB profile page.

The generic ingredient in ERY-TAB is erythromycin. There are ninety-nine drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the erythromycin profile page.

Summary for 062298

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Antibacterials
Formulation / Manufacturing:see details

Pharmacology for NDA: 062298

Ingredient-typeMacrolides
Physiological EffectDecreased Sebaceous Gland Activity

Medical Subject Heading (MeSH) Categories for 062298

Suppliers and Packaging for NDA: 062298

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ERY-TAB
erythromycin
TABLET, DELAYED RELEASE;ORAL 062298 ANDA KAISER FOUNDATION HOSPITALS 0179-1427 0179-1427-88 600 TABLET, DELAYED RELEASE in 1 BOTTLE (0179-1427-88)
ERY-TAB
erythromycin
TABLET, DELAYED RELEASE;ORAL 062298 ANDA STAT Rx USA LLC 16590-089 16590-089-30 30 TABLET, DELAYED RELEASE in 1 BOTTLE (16590-089-30)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, DELAYED RELEASE;ORALStrength250MG
Approval Date:Approved Prior to Jan 1, 1982TE:RLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, DELAYED RELEASE;ORALStrength500MG
Approval Date:Approved Prior to Jan 1, 1982TE:RLD:No

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET, DELAYED RELEASE;ORALStrength333MG
Approval Date:Mar 29, 1982TE:RLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Merck
Cantor Fitzgerald
AstraZeneca
Novartis
Johnson and Johnson
Queensland Health
Citi
Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot